DK1835922T3 - Kombinationsbehandling mod multipel sklerose - Google Patents
Kombinationsbehandling mod multipel skleroseInfo
- Publication number
- DK1835922T3 DK1835922T3 DK05823965T DK05823965T DK1835922T3 DK 1835922 T3 DK1835922 T3 DK 1835922T3 DK 05823965 T DK05823965 T DK 05823965T DK 05823965 T DK05823965 T DK 05823965T DK 1835922 T3 DK1835922 T3 DK 1835922T3
- Authority
- DK
- Denmark
- Prior art keywords
- multiple sclerosis
- cda
- alpha
- agent
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63867404P | 2004-12-22 | 2004-12-22 | |
| EP04106910 | 2004-12-22 | ||
| PCT/EP2005/056943 WO2006067134A1 (en) | 2004-12-22 | 2005-12-20 | Combination treatment for multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1835922T3 true DK1835922T3 (da) | 2009-08-03 |
Family
ID=35789196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05823965T DK1835922T3 (da) | 2004-12-22 | 2005-12-20 | Kombinationsbehandling mod multipel sklerose |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100129353A1 (el) |
| EP (1) | EP1835922B1 (el) |
| JP (1) | JP2008524310A (el) |
| AT (1) | ATE431740T1 (el) |
| AU (1) | AU2005318183B2 (el) |
| CA (1) | CA2590471A1 (el) |
| CY (1) | CY1109316T1 (el) |
| DE (1) | DE602005014570D1 (el) |
| DK (1) | DK1835922T3 (el) |
| ES (1) | ES2325552T3 (el) |
| HR (1) | HRP20090417T1 (el) |
| IL (1) | IL183924A (el) |
| NO (1) | NO20073635L (el) |
| PL (1) | PL1835922T3 (el) |
| PT (1) | PT1835922E (el) |
| SI (1) | SI1835922T1 (el) |
| WO (1) | WO2006067134A1 (el) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521565B1 (fr) * | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2534487B1 (fr) * | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9206318D0 (en) * | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| DE69230142T2 (de) * | 1991-05-15 | 2000-03-09 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US6225447B1 (en) * | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| DK1024191T3 (da) * | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
| US5208327A (en) * | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JP3720353B2 (ja) * | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
| GB9712818D0 (en) * | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| US6194395B1 (en) * | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| PT2336184E (pt) * | 2002-02-25 | 2015-03-09 | Biogen Idec Inc | Administração de agentes para o tratamento da inflamação |
| ES2584183T3 (es) * | 2003-03-28 | 2016-09-26 | Ares Trading S.A. | Formulaciones de cladribina para suministro mejorado oral y transmucosa |
-
2005
- 2005-12-20 ES ES05823965T patent/ES2325552T3/es active Active
- 2005-12-20 PL PL05823965T patent/PL1835922T3/pl unknown
- 2005-12-20 JP JP2007547483A patent/JP2008524310A/ja not_active Withdrawn
- 2005-12-20 US US11/722,487 patent/US20100129353A1/en not_active Abandoned
- 2005-12-20 WO PCT/EP2005/056943 patent/WO2006067134A1/en active Application Filing
- 2005-12-20 PT PT05823965T patent/PT1835922E/pt unknown
- 2005-12-20 CA CA002590471A patent/CA2590471A1/en not_active Abandoned
- 2005-12-20 AT AT05823965T patent/ATE431740T1/de active
- 2005-12-20 EP EP05823965A patent/EP1835922B1/en active Active
- 2005-12-20 SI SI200530731T patent/SI1835922T1/sl unknown
- 2005-12-20 AU AU2005318183A patent/AU2005318183B2/en not_active Ceased
- 2005-12-20 DK DK05823965T patent/DK1835922T3/da active
- 2005-12-20 DE DE602005014570T patent/DE602005014570D1/de active Active
-
2007
- 2007-06-14 IL IL183924A patent/IL183924A/en not_active IP Right Cessation
- 2007-07-13 NO NO20073635A patent/NO20073635L/no not_active Application Discontinuation
-
2009
- 2009-07-27 HR HR20090417T patent/HRP20090417T1/xx unknown
- 2009-08-12 CY CY20091100869T patent/CY1109316T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005318183A1 (en) | 2006-06-29 |
| WO2006067134A1 (en) | 2006-06-29 |
| SI1835922T1 (sl) | 2009-10-31 |
| JP2008524310A (ja) | 2008-07-10 |
| US20100129353A1 (en) | 2010-05-27 |
| EP1835922A1 (en) | 2007-09-26 |
| PT1835922E (pt) | 2009-07-08 |
| AU2005318183B2 (en) | 2011-03-31 |
| CY1109316T1 (el) | 2014-07-02 |
| IL183924A (en) | 2010-11-30 |
| ES2325552T3 (es) | 2009-09-08 |
| HRP20090417T1 (en) | 2009-09-30 |
| ATE431740T1 (de) | 2009-06-15 |
| EP1835922B1 (en) | 2009-05-20 |
| IL183924A0 (en) | 2007-10-31 |
| DE602005014570D1 (el) | 2009-07-02 |
| CA2590471A1 (en) | 2006-06-29 |
| NO20073635L (no) | 2007-09-24 |
| PL1835922T3 (pl) | 2009-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2506085A (en) | Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV | |
| CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| NO20052362L (no) | Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner | |
| UA101309C2 (ru) | Антагонисты активина-actrii и их применение для повышения уровня эритроцитов | |
| FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
| NO332893B1 (no) | Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi | |
| EA200600696A1 (ru) | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| WO2007058990A3 (en) | Therapy using cytokine inhibitors | |
| NO20064287L (no) | Dalbavancin-materialer for behandling av bakterielle infeksjoner | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| DE60114406D1 (de) | Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen | |
| WO2003049694A3 (en) | Methods of therapy for non-hodgkin's lymphoma | |
| SG160323A1 (en) | Methods for controlling angiogenesis and cell proliferation | |
| HK1112721A1 (en) | Tissue disruption treatment and composition for use thereof | |
| CY1113488T1 (el) | Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| ATE413187T1 (de) | Pharmazeutische zusammensetzungen mit interferon- tau | |
| TW200420290A (en) | Methods for the treatment, prevention and management of macular degeneration | |
| JP2003528919A5 (el) | ||
| DK1835922T3 (da) | Kombinationsbehandling mod multipel sklerose | |
| TW200628162A (en) | Combination treatment for multiple sclerosis | |
| EA200801670A1 (ru) | Комбинированная противораковая терапия с перфузией изолированного органа | |
| WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer | |
| RU2008137226A (ru) | Способ и композиция для защиты от радиации |